Biodexa Pharmaceuticals Reports Preliminary Results for 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy BDRX?
Source: Newsfilter
- R&D Spending Decline: In 2025, Biodexa's R&D expenditure was £3.96 million, a 27.2% decrease from £5.44 million in 2024, reflecting a strategic shift in prioritizing projects amid resource constraints, which may impact future product development timelines.
- Clinical Trial Progress: The company successfully initiated the Phase 3 Serenta trial for eRapa in 2025, enrolling 168 patients across the US and Europe, with recruitment expected to complete in the next 18 months, potentially offering new treatment options for FAP patients and significant market potential.
- Improved Financing Situation: Biodexa raised £10 million through a registered offering in 2025 and secured an additional £20 million grant from the Cancer Prevention and Research Institute of Texas, providing essential funding for operations and R&D, thereby enhancing financial stability.
- Strategic Transition Completed: The company completed its transition from a drug delivery firm to a higher-value therapeutics company in 2025, with the introduction of MTX240, focusing its pipeline on gastrointestinal and oncology areas, which is expected to enhance its competitive position in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDRX
About BDRX
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biodexa Pharmaceuticals Reports Preliminary Results for 2025
- R&D Spending Decline: In 2025, Biodexa's R&D expenditure was £3.96 million, a 27.2% decrease from £5.44 million in 2024, reflecting a strategic shift in prioritizing projects amid resource constraints, which may impact future product development timelines.
- Clinical Trial Progress: The company successfully initiated the Phase 3 Serenta trial for eRapa in 2025, enrolling 168 patients across the US and Europe, with recruitment expected to complete in the next 18 months, potentially offering new treatment options for FAP patients and significant market potential.
- Improved Financing Situation: Biodexa raised £10 million through a registered offering in 2025 and secured an additional £20 million grant from the Cancer Prevention and Research Institute of Texas, providing essential funding for operations and R&D, thereby enhancing financial stability.
- Strategic Transition Completed: The company completed its transition from a drug delivery firm to a higher-value therapeutics company in 2025, with the introduction of MTX240, focusing its pipeline on gastrointestinal and oncology areas, which is expected to enhance its competitive position in the market.
See More
Biodexa Pharmaceuticals Adjusts ADR Ratio
- ADR Ratio Change: Biodexa Pharmaceuticals announced a change in its American Depositary Receipts (ADR) ratio from one ADR representing 100,000 ordinary shares to one ADR representing 500,000 ordinary shares, aimed at increasing the market price of its ADRs to comply with Nasdaq's minimum bid price requirement of $1.00 per share.
- Effective Date Set: The effective date for this ratio change is expected to be on or about April 6, 2026, providing investors with necessary preparation time to adapt to the new ADR structure.
- Compliance Enhancement: By adjusting the ADR ratio, Biodexa aims to enhance its compliance with Nasdaq, ensuring its stock can continue to be listed on the exchange, thereby maintaining investor confidence and market stability.
- Investor Impact: This move may not only improve the liquidity of the ADRs but also attract more investor attention to Biodexa, thus supporting the company's future financing and growth initiatives.
See More
Biodexa Supports Life's a Polyp Foundation for FAP Patients
- First FAP Advocacy Group: Biodexa Pharmaceuticals PLC officially supports the launch of the Life's a Polyp Foundation, the first U.S.-based advocacy group dedicated to patients with Familial Adenomatous Polyposis (FAP), aiming to provide essential resources and support while raising awareness of this rare genetic condition.
- Financial Support and Collaboration: Biodexa has provided initial financial grants to the foundation, demonstrating its commitment to addressing unmet needs of FAP patients and amplifying patient voices in rare disease research and care through collaboration with the foundation.
- Innovative Treatment Program: Biodexa's lead program, eRapa, is currently in the registrational Phase 3 Serenta trial as the first potential non-surgical treatment for FAP, with over 20% of patients enrolled and Fast Track designation from the FDA, indicating its potential to enhance patient survival rates.
- Patient-Centric Mission: Steve Ellul, Biodexa's CBO, emphasized that supporting the Life's a Polyp Foundation aligns with their goal to improve the lives of FAP patients through advocacy, innovation, and collaboration, reflecting the company's strong commitment to patient-centric initiatives.
See More
Biodexa Secures Exclusive License for Otsuka's OPB-171775, a Novel GIST Treatment
- Exclusive Licensing Agreement: Biodexa has entered into an exclusive licensing agreement with Otsuka Pharmaceutical to develop and commercialize OPB-171775 globally, except in Japan, which is expected to significantly enhance the company's market position in rare diseases.
- Innovative Mechanism: MTX240 utilizes molecular glue technology to effectively overcome TKI resistance by inducing interactions between PDE3a and SLFN12 proteins, offering a novel therapeutic approach that may benefit a large number of GIST patients.
- Market Potential: With approximately 3,000-4,000 GIST patients annually in the U.S., MTX240's unique mechanism is poised to address the treatment gap for TKI-resistant patients, and the global GIST market is projected to grow at an annual rate of 6-10% to reach about $1.3 billion by 2032.
- Patent Protection: MTX240 is protected by composition of matter patents in the U.S., Europe, and Japan, extending through 2037, ensuring its competitive advantage in the market while providing legal safeguards for future development and commercialization.
See More
Biodexa Pharmaceuticals Appoints Fiona Sharp as CFO, Shares Rise 3.45%
- Executive Transition: Biodexa Pharmaceuticals has promoted Fiona Sharp to Chief Financial Officer and Company Secretary, effective immediately, aiming to strengthen financial management and enhance operational efficiency within the company.
- Succession Plan: Sharp succeeds Stephen Stamp, who will continue as Chief Executive Officer, ensuring stability and continuity in the company's leadership during this transition.
- Financial Expertise: Having served as Group Financial Controller since December 2019, Sharp brings extensive financial management experience, previously holding the position of Assistant Director of Finance at Hywel Dda University Health Board, which is expected to enhance the company's financial strategy.
- Market Reaction: BDRX shares are currently trading at $2.54, reflecting a 3.45% increase from the previous trading day, indicating positive market sentiment regarding the new CFO's appointment and confidence in the company's future growth prospects.
See More
B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
B. Riley Financial Performance: B. Riley Financial Inc reported a significant turnaround with earnings of $4.50 per share for Q2, compared to a loss of $14.35 per share a year ago, and sales increased to $225.302 million from $94.885 million, leading to a 25% rise in share price during pre-market trading.
Pre-Market Stock Movements: Several stocks experienced notable pre-market trading movements, with Biodexa Pharmaceuticals gaining 51.4% and Venus Concept surging 31.1%, while Radiopharm Theranostics saw a sharp decline of 39.8%.
Other Notable Gainers: Other stocks that rose in pre-market trading included Uniqure NV (+14.1%), Adagio Medical Holdings (+11.7%), and Sunrise New Energy (+10.5%), reflecting a mix of recovery and growth in various sectors.
Significant Losers: Stocks that faced declines included iRobot Corp, which fell 23.2% after filing for Chapter 11 bankruptcy, and Saverone 2014 Ltd, which tumbled 37.8% following a previous gain, indicating volatility in the market.
See More
Biodexa Pharmaceuticals Reports Preliminary Results for 2025
- R&D Spending Decline: In 2025, Biodexa's R&D expenditure was £3.96 million, a 27.2% decrease from £5.44 million in 2024, reflecting a strategic shift in prioritizing projects amid resource constraints, which may impact future product development timelines.
- Clinical Trial Progress: The company successfully initiated the Phase 3 Serenta trial for eRapa in 2025, enrolling 168 patients across the US and Europe, with recruitment expected to complete in the next 18 months, potentially offering new treatment options for FAP patients and significant market potential.
- Improved Financing Situation: Biodexa raised £10 million through a registered offering in 2025 and secured an additional £20 million grant from the Cancer Prevention and Research Institute of Texas, providing essential funding for operations and R&D, thereby enhancing financial stability.
- Strategic Transition Completed: The company completed its transition from a drug delivery firm to a higher-value therapeutics company in 2025, with the introduction of MTX240, focusing its pipeline on gastrointestinal and oncology areas, which is expected to enhance its competitive position in the market.
See More
Biodexa Pharmaceuticals Adjusts ADR Ratio
- ADR Ratio Change: Biodexa Pharmaceuticals announced a change in its American Depositary Receipts (ADR) ratio from one ADR representing 100,000 ordinary shares to one ADR representing 500,000 ordinary shares, aimed at increasing the market price of its ADRs to comply with Nasdaq's minimum bid price requirement of $1.00 per share.
- Effective Date Set: The effective date for this ratio change is expected to be on or about April 6, 2026, providing investors with necessary preparation time to adapt to the new ADR structure.
- Compliance Enhancement: By adjusting the ADR ratio, Biodexa aims to enhance its compliance with Nasdaq, ensuring its stock can continue to be listed on the exchange, thereby maintaining investor confidence and market stability.
- Investor Impact: This move may not only improve the liquidity of the ADRs but also attract more investor attention to Biodexa, thus supporting the company's future financing and growth initiatives.
See More
Biodexa Supports Life's a Polyp Foundation for FAP Patients
- First FAP Advocacy Group: Biodexa Pharmaceuticals PLC officially supports the launch of the Life's a Polyp Foundation, the first U.S.-based advocacy group dedicated to patients with Familial Adenomatous Polyposis (FAP), aiming to provide essential resources and support while raising awareness of this rare genetic condition.
- Financial Support and Collaboration: Biodexa has provided initial financial grants to the foundation, demonstrating its commitment to addressing unmet needs of FAP patients and amplifying patient voices in rare disease research and care through collaboration with the foundation.
- Innovative Treatment Program: Biodexa's lead program, eRapa, is currently in the registrational Phase 3 Serenta trial as the first potential non-surgical treatment for FAP, with over 20% of patients enrolled and Fast Track designation from the FDA, indicating its potential to enhance patient survival rates.
- Patient-Centric Mission: Steve Ellul, Biodexa's CBO, emphasized that supporting the Life's a Polyp Foundation aligns with their goal to improve the lives of FAP patients through advocacy, innovation, and collaboration, reflecting the company's strong commitment to patient-centric initiatives.
See More
Biodexa Secures Exclusive License for Otsuka's OPB-171775, a Novel GIST Treatment
- Exclusive Licensing Agreement: Biodexa has entered into an exclusive licensing agreement with Otsuka Pharmaceutical to develop and commercialize OPB-171775 globally, except in Japan, which is expected to significantly enhance the company's market position in rare diseases.
- Innovative Mechanism: MTX240 utilizes molecular glue technology to effectively overcome TKI resistance by inducing interactions between PDE3a and SLFN12 proteins, offering a novel therapeutic approach that may benefit a large number of GIST patients.
- Market Potential: With approximately 3,000-4,000 GIST patients annually in the U.S., MTX240's unique mechanism is poised to address the treatment gap for TKI-resistant patients, and the global GIST market is projected to grow at an annual rate of 6-10% to reach about $1.3 billion by 2032.
- Patent Protection: MTX240 is protected by composition of matter patents in the U.S., Europe, and Japan, extending through 2037, ensuring its competitive advantage in the market while providing legal safeguards for future development and commercialization.
See More
Biodexa Pharmaceuticals Appoints Fiona Sharp as CFO, Shares Rise 3.45%
- Executive Transition: Biodexa Pharmaceuticals has promoted Fiona Sharp to Chief Financial Officer and Company Secretary, effective immediately, aiming to strengthen financial management and enhance operational efficiency within the company.
- Succession Plan: Sharp succeeds Stephen Stamp, who will continue as Chief Executive Officer, ensuring stability and continuity in the company's leadership during this transition.
- Financial Expertise: Having served as Group Financial Controller since December 2019, Sharp brings extensive financial management experience, previously holding the position of Assistant Director of Finance at Hywel Dda University Health Board, which is expected to enhance the company's financial strategy.
- Market Reaction: BDRX shares are currently trading at $2.54, reflecting a 3.45% increase from the previous trading day, indicating positive market sentiment regarding the new CFO's appointment and confidence in the company's future growth prospects.
See More
B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
B. Riley Financial Performance: B. Riley Financial Inc reported a significant turnaround with earnings of $4.50 per share for Q2, compared to a loss of $14.35 per share a year ago, and sales increased to $225.302 million from $94.885 million, leading to a 25% rise in share price during pre-market trading.
Pre-Market Stock Movements: Several stocks experienced notable pre-market trading movements, with Biodexa Pharmaceuticals gaining 51.4% and Venus Concept surging 31.1%, while Radiopharm Theranostics saw a sharp decline of 39.8%.
Other Notable Gainers: Other stocks that rose in pre-market trading included Uniqure NV (+14.1%), Adagio Medical Holdings (+11.7%), and Sunrise New Energy (+10.5%), reflecting a mix of recovery and growth in various sectors.
Significant Losers: Stocks that faced declines included iRobot Corp, which fell 23.2% after filing for Chapter 11 bankruptcy, and Saverone 2014 Ltd, which tumbled 37.8% following a previous gain, indicating volatility in the market.
See More
